If you have been wondering whether CRISPR Therapeutics at around $57 a share is a bargain or a bubble, you are not alone. This stock sits at the crossroads of high science and high expectations. The ...
CRISPR Therapeutics recently drew attention as updates highlighted progress in its gene-editing pipeline, including early-stage studies of CTX310, an in vivo therapy designed to lower LDL cholesterol ...
Investor's Business Daily on MSN
Stocks to watch: CRISPR Therapeutics sees relative strength rating rise to 82
CRISPR Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 82.
Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.
Jesse Tettero presented data supporting the use of a measurable residual disease (MRD) surrogate endpoint in acute myeloid leukemia (AML) research. Through the Harmony Alliance study of 1,858 pooled ...
Dyadic International, Inc. ( DYAI) IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 December 9, 2025 9:30 AM EST Good day, and welcome to the iAcessAlpha Virtual Best Ideas winter ...
Institute of Neuroscience, Howard Hughes Medical Institute, University of Oregon, Eugene, United States ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback